1-2 of 2
Keywords: Tumor necrosis factor
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Current Use of Interferons, Interleukin-2 and Tumor Necrosis Factor in Renal Cell Cancer

Available to Purchase
Subject Area:
Further Areas
M. Wirth
Journal: Urologia Internationalis
Urol Int (1991) 47 (4): 219–230.
https://doi.org/10.1159/000282226
Published Online: 03 February 2010
...M. Wirth Cytokines such as interferons, interleukin-2 and tumor necrosis factor have been widely tested in the treatment of advanced renal cell cancer. However, the rates of objective remissions (PR and CR) are disappointing and rarely exceed 20% overall. Until now, a definitive cure of a patient...
View article titled, The Current Use of Interferons, Interleukin-2 and Tumor Necrosis Factor in Renal Cell Cancer
Open the PDF for The Current Use of Interferons, Interleukin-2 and Tumor Necrosis Factor in Renal Cell Cancer in another window
Journal Articles

Promotion of Metastases by Tumor Necrosis Factor in Rats Bearing Dunning R3327 MAT-LyLu Prostatic Cancer

Available to Purchase
Subject Area:
Further Areas
Tatsuo Iizumi, Tsunetada Yazaki, Takashi Umeda, Gen-Ichiro Soma
Journal: Urologia Internationalis
Urol Int (1993) 51 (2): 85–88.
https://doi.org/10.1159/000282519
Published Online: 03 February 2010
...Tatsuo Iizumi; Tsunetada Yazaki; Takashi Umeda; Gen-Ichiro Soma We examined the effects of recombinant human tumor necrosis factor (rTNF) on highly metastatic rat prostatic cancer, Dunning R3327 MAT-LyLu, in vivo. It seemed that the inhibition of tumor growth needed more than 5 × 10 5 units of rTNF...
View article titled, Promotion of Metastases by Tumor Necrosis Factor in Rats Bearing Dunning R3327 MAT-LyLu Prostatic Cancer
Open the PDF for Promotion of Metastases by Tumor Necrosis Factor in Rats Bearing Dunning R3327 MAT-LyLu Prostatic Cancer in another window